# Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct07469306/  
OnCo record `nct07469306` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fOLFOX (5-FU, leucovorin, oxaliplatin), capecitabine and tislelizumab in colorectal cancer, run by Fujian Cancer Hospital, not yet recruiting.

## Summary

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07469306 by Fujian Cancer Hospital, with a registry enrolment figure of 130 participants, started 2026-08-10 and due to reach its primary completion in 2027-08-10. Interventions recorded: Modified Short-course radiotherapy; Long-course radiotherapy; Oxaliplatin; Capecitabine; Tislelizumab; Capecitabine; Tislelizumab. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Complete Response (CR) Rate. Colorectal eligibility wording from the registry: "* Pathologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07469306
- Phase: 2
- Setting: Prospective, Randomized, Phase II Trial of Modified Short-Course Radiotherapy Plus CAPOX and Tislelizumab Versus Long-Course Chemoradiotherapy Plus Tislelizumab for Locally Advanced Rectal Cancer
- Sponsor: Fujian Cancer Hospital
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT07469306: https://clinicaltrials.gov/study/NCT07469306

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07469306.json